Dec 15 (Reuters) – UK’s health regulator on Monday approved GSK’s twice-yearly drug for use as an add-on treatment for asthma in patients aged 12 and older, as well as for a chronic inflammatory sinus condition in adults.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)
Brought to you by www.srnnews.com
